GSK-F1
Based on 1 Customer Validation
GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 95.06%
- CAS No.: 1402345-92-9
- 화학식: C27H18F5N5O4S
- 분자량:603.52
-
보관:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-18748
BQR-695PI4K Inhibitor -
HY-125118
GSK-A1PI4KIIIα Inhibitor -
HY-108313
T-00127_HEV1PI4K Inhibitor -
HY-12912
KDU691Plasmodium PI4K Inhibitor -
HY-106005
MMV390048PI4K Inhibitor -
HY-103583
KDU731PI4K Inhibitor -
HY-106005R
MMV390048 (Standard)Reference Standard -
HY-112613
UCB9608PI4KIIIβ Inhibitor -
HY-N1412
1,3-Dicaffeoylquinic acidAntioxidant Agent -
HY-103583R
KDU731 (Standard)Reference Standard -
HY-108313R
T-00127_HEV1 (Standard)Reference Standard -
HY-N1412R
1,3-Dicaffeoylquinic acid (Standard)Antioxidant Agent
Biological Activity
제품 설명
IC50 & Target
|
PI4KA 8.0 (pIC50) |
PI3KD 6.4 (pIC50) |
PI4KB 5.9 (pIC50) |
PI3KB 5.9 (pIC50) |
PI3KG 5.9 (pIC50) |
PI3KA 5.8 (pIC50) |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1402345-92-9
-
Appearance Solid
-
분자량 603.52
-
화학식 C27H18F5N5O4S
-
Color White to off-white
-
SMILES
O=S(C1=CC(C2=CC3=C(N=C(N)N(C4=CC=CC=C4C(F)(F)F)C3=O)C=C2)=CN=C1OC)(NC5=CC=C(F)C=C5F)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
용액&용해도
In Vitro:
DMSO : 125 mg/mL (207.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
순도&문서
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6569 mL | 8.2847 mL | 16.5695 mL | 41.4236 mL |
| 5 mM | 0.3314 mL | 1.6569 mL | 3.3139 mL | 8.2847 mL | |
| 10 mM | 0.1657 mL | 0.8285 mL | 1.6569 mL | 4.1424 mL | |
| 15 mM | 0.1105 mL | 0.5523 mL | 1.1046 mL | 2.7616 mL | |
| 20 mM | 0.0828 mL | 0.4142 mL | 0.8285 mL | 2.0712 mL | |
| 25 mM | 0.0663 mL | 0.3314 mL | 0.6628 mL | 1.6569 mL | |
| 30 mM | 0.0552 mL | 0.2762 mL | 0.5523 mL | 1.3808 mL | |
| 40 mM | 0.0414 mL | 0.2071 mL | 0.4142 mL | 1.0356 mL | |
| 50 mM | 0.0331 mL | 0.1657 mL | 0.3314 mL | 0.8285 mL | |
| 60 mM | 0.0276 mL | 0.1381 mL | 0.2762 mL | 0.6904 mL | |
| 80 mM | 0.0207 mL | 0.1036 mL | 0.2071 mL | 0.5178 mL | |
| 100 mM | 0.0166 mL | 0.0828 mL | 0.1657 mL | 0.4142 mL |
GSK-F1 Related Classifications
HY-100603 Related Classifications
Powered by Bioz